Evidence map›Paper›PMID 38750530›Full record

ArticleBMC research notes2024

Concepts of lines of therapy in cancer treatment: findings from an expert interview-based study.

Lisa Falchetto, Bernd Bender, Ian Erhard, Kim N Zeiner, Jan A Stratmann, Florestan J Koll, Sebastian Wagner, Marcel Reiser, Khayal Gasimli, Angelika Stehle and 4 more

Abstract read
In one paragraph

Article in BMC research notes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Lisa Falchetto *Institute for Digital Medicine and Clinical Data Science, Goethe University Frankfurt, Faculty of Medicine, Frankfurt, Germany.
Bernd Bender *Institute for Digital Medicine and Clinical Data Science, Goethe University Frankfurt, Faculty of Medicine, Frankfurt, Germany. B.Bender@med.uni-frankfurt.de.
Ian ErhardInstitute for Digital Medicine and Clinical Data Science, Goethe University Frankfurt, Faculty of Medicine, Frankfurt, Germany.
Kim N ZeinerDepartment for Dermatology, Venerology and Allergology, University Hospital Frankfurt, Frankfurt, Germany.
Jan A StratmannMedical Department 2 (Hematology/Oncology), Center for Internal Medicine, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
Florestan J KollDepartment of Urology, University Hospital Frankfurt, Frankfurt, Germany.
Sebastian WagnerMedical Department 2 (Hematology/Oncology), Center for Internal Medicine, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
Marcel ReiserPIOH Praxis Internistischer Onkologie und Hämatologie, Cologne, Germany.
Khayal GasimliClinic for Gynecology and Obstetrics, University Hospital Frankfurt, Frankfurt, Germany.
Angelika StehleDepartment for Internal Medicine 1, University Hospital Frankfurt, Frankfurt, Germany.
Martin VossDepartment Neuro-Oncology, University Hospital Frankfurt, Frankfurt, Germany.
Olivier BalloMedical Department 2 (Hematology/Oncology), Center for Internal Medicine, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany.
Jörg Janne VehreschildInstitute for Digital Medicine and Clinical Data Science, Goethe University Frankfurt, Faculty of Medicine, Frankfurt, Germany.
Daniel MaierInstitute for Digital Medicine and Clinical Data Science, Goethe University Frankfurt, Faculty of Medicine, Frankfurt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe concept of lines of therapy (LOT) in cancer treatment is often considered for decision making in tumor boards and clinical management, but lacks a common definition across medical specialties. The complexity and heterogeneity of malignancies and treatment modalities contribute to an inconsistent understanding of LOT among physicians. This study assesses the heterogeneity of understandings of the LOT concept, its major dimensions, and criteria from the perspective of physicians of different specialties with an oncological focus in Germany. Semi-structured expert interviews with nine physicians were conducted and evaluated using qualitative content analysis.

resultsMost interviewees agreed that there is no single definition for LOT and found it difficult to explicate their understanding. A majority of experts stated that they had already encountered misunderstandings with colleagues regarding LOT and that they had problems with deciphering LOT from the medical records of their patients. Disagreement emerged about the roles of the following within the LOT concept: maintenance therapy, treatment intention, different therapy modalities, changing pharmaceutical agents, and therapy breaks. Respondents predominantly considered the same criteria as decisive for the definition of LOT as for a change in LOT (e.g., the occurrence of a progression event or tumor recurrence).

Indexed as

NeoplasmsAdultFemaleGermanyHumansInterviews as TopicMaleMiddle AgedPhysiciansQualitative Researchcancer treatmentExpert interviewLines of therapyTherapy planning

Identifiers

PMID38750530
PMCPMC11094945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.